Institute of Nuclear Medicine with PET Center, Wilhelminenspital, Montleartstrasse 37, Vienna, Austria.
Oncology. 2011;80(5-6):326-9. doi: 10.1159/000329808. Epub 2011 Jul 25.
Peptide receptor-targeted radionuclide therapy (PRRT) of somatostatin receptor (SR)-expressing neuroendocrine tumors (NETs) has become an established therapeutic option in patients with advanced NETs. The aim of this study was to compare the lesion detection rate of (99m)Tc-EDDA/HYNIC-TOC, a newly developed tracer for NET imaging, with (177)Lu-DOTATATE used for PRRT.
8 patients (4 women, 4 men, age range 46-76 years) with histologically proven NETs, who showed high SR loads by (99m)Tc-EDDA/HYNIC-TOC scintigraphy, were treated with (177)Lu-DOTATATE. After treatment, all patients were subjected to whole-body scintigraphy with additional low-dose single-photon emission computed tomography (SPECT-CT) of the chest and abdomen.
All patients demonstrated (177)Lu-DOTATATE accumulation in all lesions previously detected by (99m)Tc- EDDA/HYNIC-TOC scintigraphy. Three patients showed additional lesions in the liver and lungs.
SPECT-CT after (177)Lu-DOTATATE therapy may be helpful in detecting additional lesions not seen using (99m)Tc-EDDA/HYNIC-TOC. This could reflect the broader affinity of (177)Lu-DOTATATE for SRs compared with (99m)Tc-EDDA/HYNIC-TOC.
肽受体靶向放射性核素治疗（PRRT）表达生长抑素受体（SR）的神经内分泌肿瘤（NETs）已成为晚期 NETs 患者的一种既定治疗选择。本研究旨在比较新型 NET 成像示踪剂 (99m)Tc-EDDA/HYNIC-TOC 与用于 PRRT 的 (177)Lu-DOTATATE 的病灶检出率。
8 名（4 女 4 男，年龄 46-76 岁）经组织学证实的 NETs 患者，（99m)Tc-EDDA/HYNIC-TOC 闪烁显像显示高 SR 负荷，接受 (177)Lu-DOTATATE 治疗。治疗后，所有患者均接受全身闪烁显像，并对胸部和腹部进行低剂量单光子发射计算机断层扫描（SPECT-CT）。
所有患者均显示先前用 (99m)Tc-EDDA/HYNIC-TOC 闪烁显像检测到的所有病灶均有 (177)Lu-DOTATATE 聚集。3 例患者在肝脏和肺部发现额外病灶。
(177)Lu-DOTATATE 治疗后的 SPECT-CT 可能有助于检测到使用 (99m)Tc-EDDA/HYNIC-TOC 无法发现的额外病灶。这可能反映了 (177)Lu-DOTATATE 与 (99m)Tc-EDDA/HYNIC-TOC 相比对 SR 的广泛亲和力。
